» Articles » PMID: 35330210

When Nothing Goes Right: Risk Factors and Biomarkers of Right Heart Failure After Left Ventricular Assist Device Implantation

Abstract

Right heart failure (RHF) is a severe complication after left ventricular assist device (LVAD) implantation. The aim of this study was to analyze the incidence, risk factors, and biomarkers for late RHF including the possible superiority of the device and implantation method. This retrospective, single-center study included patients who underwent LVAD implantation between 2014 and 2018. Primary outcome was freedom from RHF over one-year after LVAD implantation; secondary outcomes included pre- and postoperative risk factors and biomarkers for RHF. Of the 145 consecutive patients (HeartMate 3/HVAD: n = 70/75; female: 13.8%), thirty-one patients (21.4%) suffered RHF after a mean LVAD support of median (IQR) 105 (118) days. LVAD implantation method (less invasive: 46.7% vs. 35.1%, = 0.29) did not differ significantly in patients with or without RHF, whereas the incidence of RHF was lower in HeartMate 3 vs. HVAD patients (12.9% vs. 29.3%, = 0.016). Multivariate Cox proportional hazard analysis identified HVAD (HR 4.61, 95% CI 1.12-18.98; = 0.03), early post-op heart rate (HR 0.96, 95% CI 0.93-0.99; = 0.02), and central venous pressure (CVP) (HR 1.21, 95% CI 1.05-1.39; = 0.01) as independent risk factors for RHF, but no association of RHF with increased all-cause mortality (HR 1.00, 95% CI 0.99-1.01; = 0.50) was found. To conclude, HVAD use, lower heart rate, and higher CVP early post-op were independent risk factors for RHF following LVAD implantation.

Citing Articles

Soluble Suppression of Tumorigenicity-2 Predicts Mortality and Right Heart Failure in Patients With a Left Ventricular Assist Device.

Numan L, Aarts E, Ramjankhan F, Oerlemans M, van der Meer M, de Jonge N J Am Heart Assoc. 2024; 13(2):e029827.

PMID: 38193339 PMC: 10926819. DOI: 10.1161/JAHA.123.029827.


Right heart failure after left ventricular assist device implantation: a persistent problem.

Siems C, Aggarwal R, Shaffer A, John R Indian J Thorac Cardiovasc Surg. 2023; 39(Suppl 1):161-169.

PMID: 37525713 PMC: 10387018. DOI: 10.1007/s12055-023-01481-z.

References
1.
Sabashnikov A, Mohite P, Zych B, Garcia D, Popov A, Weymann A . Outcomes and predictors of early mortality after continuous-flow left ventricular assist device implantation as a bridge to transplantation. ASAIO J. 2014; 60(2):162-9. PMC: 3942348. DOI: 10.1097/MAT.0000000000000035. View

2.
Atluri P, Goldstone A, Fairman A, MacArthur J, Shudo Y, Cohen J . Predicting right ventricular failure in the modern, continuous flow left ventricular assist device era. Ann Thorac Surg. 2013; 96(3):857-63. PMC: 4111251. DOI: 10.1016/j.athoracsur.2013.03.099. View

3.
Schmitto J, Molitoris U, Haverich A, Strueber M . Implantation of a centrifugal pump as a left ventricular assist device through a novel, minimized approach: upper hemisternotomy combined with anterolateral thoracotomy. J Thorac Cardiovasc Surg. 2011; 143(2):511-3. DOI: 10.1016/j.jtcvs.2011.07.046. View

4.
Numan L, Ramjankhan F, Oberski D, Oerlemans M, Aarts E, Gianoli M . Propensity score-based analysis of long-term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support. ESC Heart Fail. 2021; 8(2):1596-1603. PMC: 8006731. DOI: 10.1002/ehf2.13267. View

5.
Lima B, Mack M, Gonzalez-Stawinski G . Ventricular assist devices: The future is now. Trends Cardiovasc Med. 2015; 25(4):360-9. DOI: 10.1016/j.tcm.2014.11.008. View